Skip to content

Heart benefits to AstraZeneca’s Farxiga

  • by

In taking the type 2 diabetes medication Farxiga (dapagliflozin) can give years of life to patients suffering from a common form that is heart-related failure as per the findings of a study that was that was published in JAMA Cardiology.

Although Farxiga was originally designed for treating type 2 diabetes it is now being studied and then approved to treat other diseases, too. In May of 2020 the drug was approved by the U.S. Food and Drug Administration (FDA) for use as treatment for heart failure and a lower Ejection Fraction, regardless of whether the patient is diabetic. Then , in April 2021 Farxiga was approved as a remedy for chronic kidney diseases, after clinical trials that were stopped early due to the fact that they proved an “overwhelming” benefits in this condition.

Benefits of Farxiga’s heart failure

Researchers have demonstrated that based on results from an investigational study of patients who suffer from heart failure It’s possible that taking Farxiga can add years of life for those suffering from this disease — the result was derived from the data, rather than proved, since the trial hasn’t lasted for long enough to demonstrate that the medication adds years of living. In this “exploratory study,” researchers looked at the data from a study of 474 patients with heart failure, who were randomly assigned to one of two drugs: Farxiga as well as a placebo (inactive pills). The participants were enrolled between February 2017 to August 2018 and followed up until June of 2019, with an average follow-up time in the range of 17.6 months. Visit this website for information on the Farxiga savings card.

In the participants who received Farxiga in the course in the research, 10 milligrams the drug were administered once each day in addition to regular treatments for heart disease. The main outcome that researchers wanted to determine was the duration until patients required hospitalization or an urgent care appointment that required IV (IV) treatments to treat their heart problems, or until they passed away due to heart-related causes. Based on the findings of other studies that have revealed about the connection between hospitalization due to heart failure and death due to causes of cardiovascular or any other cause The researchers then utilized the Farxiga data to determine how long people could have to live if taking the medication for the rest of their lives.

The study discovered that a person aged 65 suffering from heart failure is expected to live another 6.2 years without experiencing a cardiovascular incident if they used a placebo as well as an extra 8.3 years should they were taking Farxiga. If they examined the causes of death and the time to die for a person 65 years old taking the placebo was found as 9.1 years. For Farxiga this was 10.8 years, which is the addition of 1.7 year of living. Similar results were found when researchers calculated these outcomes for people with different ages.

“These results suggest that [Farxiga] can provide significant clinical benefits in extrapolating life expectancy and event-free,” the researchers wrote. “These results could be useful in explaining the benefits of this therapy” for patients with heart failure.